Biomarkers are employed across the entire healthcare spectrum, from biological research laboratories to patient monitoring in clinics. Biomarker diagnostics and drug therapy combinations are providing the basis for the next generation of effective and beneficial treatments for a wide range of diseases.

The “2nd Berlin Conference on IP in Life Sciences” was aimed at addressing nearly every aspect of the development of diagnostics, focusing on the entire value chain, from research and development to marketing and reimbursement. Leading European life science experts from business and research, biobanks, contract research and regulatory authorities were present at the conference, which was tailored specifically for biotech and pharma enterprises.

Programme

9:00 |

Welcome Address

 

 

 

 

H.E. Dr. Peter Boehm,
Canadian Ambassador

 

 

 

Dr. Hans-Rainer Jaenichen,
Partner
Vossius & Partner

 

    |

Key Note

 

Defining the diagnostic market and its potential

Dr. Christian Peter,
Analyst,
Sal. Oppenheim



    |

Biomarker Discovery

 

Biobanking and Biomolecular Resources Research Infrastructure BBMRI

Georges Dagher,
Inserm - Clinical Research and Therapeutics Department



    |

Biomarker Development

 

The R&D process in the pharmaceutical
industry, developing personalized
treatments

Dr. Simon Read,
Biomarker and Experimental Medicine Leader,
Roche Products Ltd.



10:30 |

Coffee Break

11:00 |

Performance Evaluation

 

Accelerating Biomarker Assay Development to Validation

Paul Smith,
Vice President - Research Markets,
Axela Inc.

CV
PPT

    |

Intellectual Property

 

Patenting nucleic acid-based biomarkers

Dr. Christian Kilger,
Patent Attorney,
Vossius & Partner



    |

Regulatory

 

The European approval pathway of diagnostic/drug combinations

Jesus Rueda,
Regulatory Affairs Manager,
EDMA



12:30 |

Lunch

13:30 |

Intellectual Property

 

Patenting peptide-based biomarkers

Dr. Ute Kilger,
Patent Attorney,
Vossius & Partner



    |

Companion Diagnostics

 

 

Diagnostic-based therapeutics in oncology

Dr. Gabriele Beer,
Diagnostics Liaison Manager,
Oncology, Roche Diagnostics



    |

Imaging

 

Combining in-vitro and imaging biomarkers for early detection of Alzheimer's Disease

Dr. Lennart Thurfjell,
Director Dignostic Software,
GE Healthcare



15:00 |

Coffee Break

15:30 |

Reimbursement

 

Pricing strategies of IVD

Dr. Jürgen Schulze,
Managing Director, Sysmex GmbH
Chairman, VDGH e.V.

 

    |

Marketing

 

Marketing strategies of IVD

Dr. Hartmut Goette,
Senior Marketing Manager,
Qiagen Women's Health

 

    |

Discussion/wrap up

 

Biomarkers and diagnostics: lessons learned

 

 

 

17:00 |

Networking

 

Cocktail Reception

Invitation Canadian Embassy and Government of Ontario

 

When & where

CONTACT & INFORMATION

 

 

Uta Holmer

Dipl.-Volkswirtin

Veranstaltungsmanagement

 

 

Telefon: +49-30-264921-53

events[at]biocom.de